Kong's Pharmaceutical Co.
Small-company pharmaceutical developer focused on discovery and development of small-molecule endocrine and oncology therapeutics. Active programs include preclinical and IND-stage oncology candidates and an endocrine/sexual-health candidate entering Phase I. The organization uses AI-enabled screening, in vitro/in vivo studies, formulation development for oral extended-release delivery, and maintains active industry partnerships and patent filings.
Industries
N/A
Nr. of Employees
small (1-50)
Kong's Pharmaceutical Co.
110 Canal Street, 4th Floor, Lowell, MA 01852
Products
CR-067 (combination therapy for erectile dysfunction)
Oral tablet program developing a combination approach intended to lower effective dosing and reduce side effects compared with existing erectile dysfunction agents.
Estrogen prodrug for post-menopausal therapy
A prodrug approach to deliver estrogen with the objective of minimizing breast cancer risk while addressing menopausal health effects.
K-119 (oral small-molecule oncology candidate)
Small-molecule oral therapy with high bioavailability developed to target cancer cells; preclinical testing completed with a focus indicated for bladder cancer and a planned IND submission.
XTL-152 series (Rac1-targeting small molecules)
Series of small-molecule candidates identified via AI-driven phenotyping and screening, focused on inhibiting the Rac1 GTPase pathway for potential treatment of multiple malignancies.
CR-067 (combination therapy for erectile dysfunction)
Oral tablet program developing a combination approach intended to lower effective dosing and reduce side effects compared with existing erectile dysfunction agents.
Estrogen prodrug for post-menopausal therapy
A prodrug approach to deliver estrogen with the objective of minimizing breast cancer risk while addressing menopausal health effects.
K-119 (oral small-molecule oncology candidate)
Small-molecule oral therapy with high bioavailability developed to target cancer cells; preclinical testing completed with a focus indicated for bladder cancer and a planned IND submission.
XTL-152 series (Rac1-targeting small molecules)
Series of small-molecule candidates identified via AI-driven phenotyping and screening, focused on inhibiting the Rac1 GTPase pathway for potential treatment of multiple malignancies.
Services
Partnering with industry sponsors and research collaborators to advance discovery and development programs in endocrine and oncology therapeutics.
Partnering with industry sponsors and research collaborators to advance discovery and development programs in endocrine and oncology therapeutics.
Expertise Areas
- Small-molecule drug discovery
- Oncology drug development
- Endocrine and hormone-related therapies
- AI-driven drug screening and phenotyping
Key Technologies
- AI-driven phenotypic screening
- Small-molecule lead optimization
- Extended-release coated oral formulations
- In vitro and in vivo preclinical models
News & Updates
Preclinical studies reported strong efficacy and safety for an oral oncology candidate; IND submission planned in the second half of 2025.
An endocrine/sexual-health candidate is expected to enter Phase I clinical trials in 2025.
Preclinical studies reported strong efficacy and safety for an oral oncology candidate; IND submission planned in the second half of 2025.
An endocrine/sexual-health candidate is expected to enter Phase I clinical trials in 2025.